Maklumat Syarikat

Kenali Alfa Invest

Tunjukkan Lagi

Maklumat Syarikat

Kenali Alfa Invest

Alfa Invest Ltd operates as an online trading broker providing retail clients with access to global financial markets. The company offers a range of trading instruments, including foreign exchange pairs, global stock indices, commodities like oil and gold, and individual stocks, all through the mechanism of CFDs. It utilizes the popular MetaTrader 5 (MT5) platform for trading. The company's stated mission is to provide a transparent, reliable, and user-friendly trading environment for both novice and experienced traders. It is registered as an International Business Company (IBC) in St. Vincent and the Grenadines.

Tunjukkan Lagi

Industri

Forex Broker RuncitUTAMA
Kewangan Perkhidmatan Lain

Perisian

Tiada data tersedia

Nampaknya bahagian ini kosong. Kembali semula untuk kemas kini!

Hubungi

Sosial

Syarikat belum mengemas kini maklumatnya.

PERKHIDMATAN INI TIDAK TERSEDIA DI RANTAU ANDA

Alfa Invest

Turki

Diasas

2022 (4 Tahun)

Diasaskan

Terakhir dalam talian: Tiada aktiviti terkini

Tuntut syarikat Lawati Laman Web

TrustScore tidak tersediaSkor tidak mencukupi untuk memaparkan trend.

Jadilah yang pertama menilai dan mengulas syarikat ini.

SKOR KESELURUHAN

Lesen

--/40

Ulasan

--/60

0 ulasan

Disediakan oleh TrustFinance

TrustScore tidak tersediaSkor tidak mencukupi untuk memaparkan trend.

Jadilah yang pertama menilai dan mengulas syarikat ini.

TrustFinance bukan penasihat kewangan berlesen dan tidak bergabung dengan mana-mana institusi kewangan di rantau anda. Kami menggalakkan anda menjalankan kajian sendiri sebelum membuat sebarang keputusan pelaburan.

Dikawal

Disyorkan

(74 ulasan)

Cyprus

2009

(17 tahun)

Maklumat Keselamatan :

CySEC

FSCA

DFSA

Maklumat Keselamatan

Amaran

Syarikat ini pada masa ini Tidak Terbukti.

Sila berwaspada terhadap risiko yang berpotensi!

Lesen

Lesen Gred A

Dikeluarkan oleh pengawal selia yang terkenal di peringkat global, lesen ini memastikan perlindungan pedagang tertinggi melalui pematuhan ketat, pengasingan dana, insurans, dan audit berkala. Penyelesaian pertikaian dan pematuhan kepada piawaian AML/CTF seterusnya meningkatkan keselamatan.

Lesen Gred B

Diberikan oleh pengawal selia serantau yang dihormati, lesen ini menawarkan langkah keselamatan yang mantap seperti pengasingan dana, pelaporan kewangan, dan skim pampasan. Walaupun kurang ketat sedikit berbanding Tahap 1, ia menyediakan perlindungan serantau yang boleh dipercayai.

Lesen Gred C

Dikeluarkan oleh pengawal selia di pasaran baru muncul, lesen ini menawarkan perlindungan asas seperti keperluan modal minimum dan dasar AML. Pengawasan kurang ketat, jadi pedagang harus berhati-hati dan mengesahkan langkah keselamatan.

Lesen Gred D

Daripada bidang kuasa dengan pengawasan minimum, lesen ini seringkali kekurangan perlindungan utama seperti pengasingan dana dan insurans. Walaupun menarik untuk fleksibiliti operasi, ia menimbulkan risiko yang lebih tinggi kepada pedagang.

Maklumat Syarikat

Kenali Alfa Invest

Tunjukkan Lagi

Maklumat Syarikat

Kenali Alfa Invest

Tunjukkan Lagi

Industri

Forex Broker RuncitUTAMA
Kewangan Perkhidmatan Lain

Perisian

Tiada data tersedia

Nampaknya bahagian ini kosong. Kembali semula untuk kemas kini!

Hubungi

Sosial

Syarikat belum mengemas kini maklumatnya.

Pengguna yang melihat Alfa Invest juga melihat…

IUX

XM

FXGT

Deriv

Exness

IUX

XM

FXGT

Deriv

Exness

Berita

TrustFinance Agensi Perisikan

Tarikh penyelidikan: Jun 28, 2026

S&P Global Ratings upgraded Alfa S.A.B. de C.V.'s credit rating from 'BBB-' to 'BBB' following the completion of its spin-off from Alpek S.A.B. de C.V., improving its business structure and leverage. The stable outlook reflects expectations of continued support from its subsidiary Sigma, which is now responsible for Alfa's financial health. Alfa's debt decreased significantly post-spin-off, and the ratings agency anticipates stable cash flow and prudent financial policies from Sigma for the next two years. Future ratings could be affected by Sigma's performance and Alfa's liquidity management.

S&P Global Ratings upgraded Alfa S.A.B. de C.V.'s credit rating from 'BBB-' to 'BBB' following the completion of its spin-off from Alpek S.A.B. de C.V., improving its business structure and leverage. The stable outlook reflects expectations of continued support from its subsidiary Sigma, which is now responsible for Alfa's financial health. Alfa's debt decreased significantly post-spin-off, and the ratings agency anticipates stable cash flow and prudent financial policies from Sigma for the next two years. Future ratings could be affected by Sigma's performance and Alfa's liquidity management.

The article explains the concept of alpha in investment, which measures the excess return of a portfolio compared to its expected return based on the capital asset pricing model (CAPM). It discusses how alpha helps investors evaluate the performance of portfolio managers by comparing realized returns with required returns adjusted for risk. A positive alpha indicates better-than-expected performance, while a negative alpha suggests underperformance. The article also emphasizes the importance of comparing funds within the same asset class and using appropriate benchmarks for accurate assessment.

The article explains the concept of alpha in investment, which measures the excess return of a portfolio compared to its expected return based on the capital asset pricing model (CAPM). It discusses how alpha helps investors evaluate the performance of portfolio managers by comparing realized returns with required returns adjusted for risk. A positive alpha indicates better-than-expected performance, while a negative alpha suggests underperformance. The article also emphasizes the importance of comparing funds within the same asset class and using appropriate benchmarks for accurate assessment.

Bicara Therapeutics Inc. announced three-year follow-up results from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab for treating HPV-negative head and neck squamous cell carcinoma (HNSCC). The study, presented at the ASCO26 medical conference, showed sustained deep responses in about 90 patients, marking a significant development in immuno-oncology. The company also launched the FORTIFI clinical trial targeting this patient group, reflecting its commitment to addressing unmet medical needs.

Bicara Therapeutics Inc. announced three-year follow-up results from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab for treating HPV-negative head and neck squamous cell carcinoma (HNSCC). The study, presented at the ASCO26 medical conference, showed sustained deep responses in about 90 patients, marking a significant development in immuno-oncology. The company also launched the FORTIFI clinical trial targeting this patient group, reflecting its commitment to addressing unmet medical needs.

Disediakan oleh Analisis AI TrustFinance

Ulasan

Alfa Invest Ulasan

Ulasan

Jumlah 0

Analisis Ulasan AI

Mari biarkan TrustFinance AI meringkaskan semua ulasan untuk anda.

Disediakan oleh Analisis AI TrustFinance

Susun

Penapis

Berita

TrustFinance Agensi Perisikan

Tarikh penyelidikan: Jun 28, 2026

S&P Global Ratings upgraded Alfa S.A.B. de C.V.'s credit rating from 'BBB-' to 'BBB' following the completion of its spin-off from Alpek S.A.B. de C.V., improving its business structure and leverage. The stable outlook reflects expectations of continued support from its subsidiary Sigma, which is now responsible for Alfa's financial health. Alfa's debt decreased significantly post-spin-off, and the ratings agency anticipates stable cash flow and prudent financial policies from Sigma for the next two years. Future ratings could be affected by Sigma's performance and Alfa's liquidity management.

The article explains the concept of alpha in investment, which measures the excess return of a portfolio compared to its expected return based on the capital asset pricing model (CAPM). It discusses how alpha helps investors evaluate the performance of portfolio managers by comparing realized returns with required returns adjusted for risk. A positive alpha indicates better-than-expected performance, while a negative alpha suggests underperformance. The article also emphasizes the importance of comparing funds within the same asset class and using appropriate benchmarks for accurate assessment.

Bicara Therapeutics Inc. announced three-year follow-up results from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab for treating HPV-negative head and neck squamous cell carcinoma (HNSCC). The study, presented at the ASCO26 medical conference, showed sustained deep responses in about 90 patients, marking a significant development in immuno-oncology. The company also launched the FORTIFI clinical trial targeting this patient group, reflecting its commitment to addressing unmet medical needs.

Disediakan oleh Analisis AI TrustFinance